Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
N/A
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 3(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05038410Not ApplicableCompleted

Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis

Role: lead

NCT03470337Phase 3Completed

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

Role: lead

NCT01845558Phase 4Completed

Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise

Role: lead

All 3 trials loaded